Abstract
The most frequent subtype of autosomal dominant inherited spinocerebellar ataxias is caused by CAG repeat expansions of more than 55 units in the ataxin-3 gene. The clinical variability of the phenotype depends on the length of the expanded repeat and the age at onset (and thus indirectly with the repeat size). Anticipation of the phenotype is most frequently associated with repeat expansions in paternal transmission. In this review we describe four clinical subphenotypes and correlate them to the respective repeat expansions. We also provide a detailed description of the neuropathological features. Finally, we discuss the current knowledge on the function of normal and dysfunction of altered ataxin-3 and how this translates to the predicted structure of the protein.
References
Schöls L, Vieira-Saecker AM, Schöls S, Przuntek H, Epplen JT, Riess O. Trinucleotide expansion within the MJD1 gene presents clinically as spinocerebellar ataxia and occurs most frequently in German SCA patients. Hum Mol Genet. 1995;4:1001–5.
Schöls L, Bauer P, Schmidt T, Schulte T, Riess O. Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol. 2004;3:291–304.
Takiyama Y, Nishizawa M, Tanaka H, Kawashima S, Sakamoto H, Karube Y, et al. The gene for Machado-Joseph disease maps to human chromosome 14q. Nat Genet. 1993;4:300–04.
Kawaguchi Y, Okamoto T, Taniwaki M, Aizawa M, Inoue M, Katayama S, et al. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet. 1994;8:221–8.
Paulson H. Spinocerebellar ataxia type 3 (SCA3). www. geneclinics.org. 2003.
Padiath QS, Srivastava AK, Roy S, Jain S, Brahmachari SK. Identification of a novel 45 repeat unstable allele associated with a disease phenotype at the MJD1/SCA3 locus. Am J Med Genet B Neuropsychiatr Genet. 2005;133:124–6.
Dürr A, Stevanin G, Cancel G, Duyckaerts C, Abbas N, Didierjean O, et al. Spinocerebellar ataxia 3 and Machado-Joseph disease: Clinical, molecular, and neuropathological features. Ann Neurol. 1996;39:490–9.
Matilla T, McCall A, Subramony SH, Zoghbi HY. Molecular and clinical correlations in spinocerebellar ataxia type 3 and Machado-Joseph disease. Ann Neurol. 1995;38:68–72.
Haberhausen G, Damian MS, Leweke F, Muller U. Spinocerebellar ataxia, type 3 (SCA3) is genetically identical to Machado-Joseph disease (MJD). J Neurol Sci. 1995;132:71–5.
Schöls L, Amoiridis G, Langkafel M, Büttner T, Przuntek H, Riess O, et al. Machado-Joseph disease mutations as the genetic basis of most spinocerebellar ataxias in Germany. J Neurol Neurosurg Psychiatry. 1995;59:449–50.
Brinkman RR, Mezei MM, Theilmann J, Almqvist E, Hayden MR. The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. Am J Hum Genet. 1997;60:1202–10.
Stevanin G, Cancel G, Didierjean O, Dürr A, Abbas N, Cassa E, et al. Linkage disequilibrium at the Machado-Joseph disease/spinal cerebellar ataxia 3 locus: Evidence for a common founder effect in French and Portuguese–Brazilian families as well as a second ancestral Portuguese–Azorean mutation. Am J Hum Genet. 1995;57:1247–50.
Iughetti P, Zatz M, Bueno MR, Marie SK. Different origins of mutations at the Machado-Joseph locus (MJD1). J Med Genet. 1996;33:439.
Gaspar C, Lopes-Cendes I, Hayes S, Goto J, Arvidsson K, Dias A, et al. Ancestral origins of the Machado-Joseph disease mutation: a worldwide haplotype study. Am J Hum Genet. 2001;68:523–8.
Abele M, Bürk K, Schöls L, Schwartz S, Besenthal I, Dichgans J, et al. The aetiology of sporadic adult-onset ataxia. Brain. 2002;125:961–8.
Schöls L, Szymanski S, Peters S, Przuntek H, Epplen JT, Hardt C, et al. Genetic background of apparently idiopathic sporadic cerebellar ataxia. Hum Genet. 2000;107:132–7.
Takiyama Y, Sakoe K, Nakano I, Nishizawa M. Machado-Joseph disease: cerebellar ataxia and autonomic dysfunction in a patient with the shortest known expanded allele (56 CAG repeat units) of the MJD1 gene. Neurology. 1997;49:604–6.
Ikeuchi T, Igarashi S, Takiyama Y, Onodera O, Oyake M, Takano H, et al. Non-Mendelian transmission in dentatorubral-pallidoluysian atrophy and Machado-Joseph disease: the mutant allele is preferentially transmitted in male meiosis. Am J Hum Genet. 1996;58:730–3.
Riess O, Epplen JT, Amoiridis G, Przuntek H, Schöls L. Transmission distortion of the mutant alleles in spinocerebellar ataxia. Hum Genet. 1997;99:282–4.
Nakano KK, Dawson DM, Spence A. Machado disease. A hereditary ataxia in Portuguese emigrants to Massachusetts. Neurology. 1972;22:49–55.
Rosenberg RN, Nyhan WL, Bay C, Shore P. Autosomal dominant striatonigral degeneration. A clinical, pathologic, and biochemical study of a new genetic disorder. Neurology. 1976;26:703–14.
Lima L, Coutinho P. Clinical criteria for diagnosis of Machado-Joseph disease: Report of a non-Azorena Portuguese family. Neurology. 1980;30:319–22.
Maruyama H, Nakamura S, Matsuyama Z, Sakai T, Doyu M, Sobue G, et al. Molecular features of the CAG repeats and clinical manifestation of Machado-Joseph disease. Hum Mol Genet. 1995;4:807–12.
Takiyama Y, Igarashi S, Rogaeva EA, Endo K, Rogaev EI, Tanaka H, et al. Evidence for inter-generational instability in the CAG repeat in the MJD1 gene and for conserved haplotypes at flanking markers amongst Japanese and Caucasian subjects with Machado-Joseph disease. Hum Mol Genet. 1995;4:1137–46.
Matsumura R, Takayanagi T, Murata K, Futamura N, Hirano M, Ueno S. Relationship of (CAG)nC configuration to repeat instability of the Machado-Joseph disease gene. Hum Genet. 1996;98:643–5.
Igarashi S, Takiyama Y, Cancel G, Rogaeva EA, Sasaki H, Wakisaka A, et al. Intergenerational instability of the CAG repeat of the gene for Machado-Joseph disease (MJD1) is affected by the genotype of the normal chromosome: Implications for the molecular mechanisms of the instability of the CAG repeat. Hum Mol Genet. 1996;5:923–32.
Limprasert P, Nouri N, Heyman RA, Nopparatana C, Kamonsilp M, Deininger PL, et al. Analysis of CAG repeat of the Machado-Joseph gene in human, chimpanzee and monkey populations: A variant nucleotide is associated with the number of CAG repeats. Hum Mol Genet. 1996;5:207–13.
Telenius H, Kremer B, Goldberg YP, Theilmann J, Andrew SE, Zeisler J, et al. Somatic and gonadal mosaicism of the Huntington disease gene CAG repeat in brain and sperm. Nat Genet. 1994;6:409–14.
Ueno S, Kondoh K, Kotani Y, Komure O, Kuno S, Kawai J, et al. Somatic mosaicism of CAG repeat in dentatorubralpallidoluysian atrophy (DRPLA). Hum Mol Genet. 1995;4:663–6.
Chong SS, McCall AE, Cota J, Subramony SH, Orr HT, Hughes MR, et al. Gametic and somatic tissue-specific heterogeneity of the expanded SCA1 CAG repeat in spinocerebellar ataxia type 1. Nat Genet. 1995;10:344–50.
Lopes-Cendes I, Maciel P, Kish S, Gaspar C, Robitaille Y, Clark HB, et al. Somatic mosaicism in the central nervous system in spinocerebellar ataxia type 1 and Machado-Joseph disease. Ann Neurol. 1996;40:199–206.
Hashida H, Goto J, Kurisaki H, Mizusawa H, Kanazawa I. Brain regional differences in the expansion of a CAG repeat in the spinocerebellar ataxias: Dentatorubral-pallidoluysian atrophy, Machado-Joseph disease, and spinocerebellar ataxia type 1. Ann Neurol. 1997;41:505–11.
Dürr A, Stevanin G, Cancel G, Abbas N, Chneiweiss H, Agid Y, et al. Gender equality in Machado-Joseph disease. Nat Genet. 1995;11:118–9.
DeStefano AL, Farrer LA, Maciel P, Gaspar C, Rouleau GA, Coutinho P, et al. Gender equality in Machado-Joseph disease. Nat Genet. 1995;11:118–9.
DeStefano AL, Cupples LA, Maciel P, Gaspar C, Radvany J, Dawson DM, et al. A familial factor independent of CAG repeat length influences age at onset of Machado-Joseph disease. Am J Hum Genet. 1996;59:119–27.
Lang AE, Rogaeva EA, Tsuda T, Hutterer J, George-Hyslop P. Homozygous inheritance of the Machado-Joseph disease gene. Ann Neurol. 1994;36:443–7.
Rosenberg RN. Machado-Joseph disease: An autosomal dominant motor system degeneration. Mov Disord. 1992;7:193–203.
Coutinho P, Andrade C. Autosomal dominant system degeneration in Portuguese families of the Azores Islands. A new genetic disorder involving cerebellar, pyramidal, extrapyramidal and spinal cord motor functions. Neurology. 1978;28:703–9.
Schöls L, Amoiridis G, Epplen JT, Langkafel M, Przuntek H, Riess O. Relations between genotype and phenotype in German patients with the Machado-Joseph disease mutation. J Neurol Neurosurg Psychiatry. 1996;61:466–70.
Schöls L, Haan J, Riess O, Amoiridis G, Przuntek H. Sleep disturbance in spinocerebellar ataxias: Is the SCA3 mutation a cause of restless legs syndrome? Neurology. 1998;51:1603–7.
Sequeiros J, Coutinho P. Epidemiology and clinical aspects of Machado-Joseph disease. In: Harding AE, Deufel T, editors. Advances in Neurology. New York: Raven Press; 1993. pp. 139–53.
Bürk K, Globas C, Bösch S, Klockgether T, Zühlke C, Daum I, et al. Cognitive deficits in spinocerebellar ataxia type 1, 2, and 3. J Neurol. 2003;250:207–11.
Klockgether T, Skalej M, Wedekind D, Luft AR, Welte D, Schulz JB, et al. Autosomal dominant cerebellar ataxia type I. MRI-based volumetry of posterior fossa structures and basal ganglia in spinocerebellar ataxia types 1, 2 and 3. Brain. 1998;121:1687–93.
Soong BW, Liu RS. Positron emission tomography in asymptomatic gene carriers of Machado-Joseph disease. J Neurol Neurosurg Psychiatry. 1998;64:499–504.
Takiyama Y, Oyanagi S, Kawashima S, Sakamoto H, Saito K, Yoshida M, et al. A clinical and pathologic study of a large Japanese family with Machado-Joseph disease tightly linked to the DNA markers on chromosome 14q. Neurology. 1994;44:1302–8.
Wüllner U, Reimold M, Abele M, Bürk K, Minnerop M, Dohmen BM, et al. Dopamine transporter positron emission tomography in spinocerebellar ataxias type 1, 2, 3, and 6. Arch Neurol. 2005;62:1280–5.
van de Warrenburg BP, Sinke RJ, Verschuuren-Bemelmans CC, Scheffer H, Brunt ER, Ippel PF, et al. Spinocerebellar ataxias in the Netherlands: Prevalence and age at onset variance analysis. Neurology. 2002;58:702–8.
Maciel P, Gaspar C, DeStefano AL, Silveira I, Coutinho P, Radvany J, et al. Correlation between CAG repeat length and clinical features in Machado-Joseph disease. Am J Hum Genet. 1995;57:54–61.
Schöls L, Amoiridis G, Buttner T, Przuntek H, Epplen JT, Riess O. Autosomal dominant cerebellar ataxia: Phenotypic differences in genetically defined subtypes? Ann Neurol. 1997;42:924–32.
Klockgether T, Kramer B, Ludtke R, Schöls L, Laccone F. Repeat length and disease progression in spinocerebellar ataxia type 3. Lancet. 1996;348:830.
Klockgether T, Ludtke R, Kramer B, Abele M, Bürk K, Schöls L, et al. The natural history of degenerative ataxia: a retrospective study in 466 patients. Brain. 1998;121:589–600.
Schmitz-Hübsch T, du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C, et al. Scale for the assessment and rating of ataxia: Development of a new clinical scale. Neurology. 2006;66:717–20.
Woods BT, Schaumburg HH. Nigro-spino-dentatal degeneration with nuclear ophthalmoplegia. A unique and partially treatable clinico-pathological entity. J Neurol Sci. 1972;17:149–66.
Buhmann C, Bussopulos A, Oechsner M. Dopaminergic response in Parkinsonian phenotype of Machado-Joseph disease. Mov Disord. 2003;18:219–21.
Tuite PJ, Rogaeva EA, George-Hyslop PH, Lang AE. Doparesponsive parkinsonism phenotype of Machado-Joseph disease: Confirmation of 14q CAG expansion. Ann Neurol. 1995;38:684–7.
Kanai K, Kuwabara S, Arai K, Sung JY, Ogawara K, Hattori T. Muscle cramp in Machado-Joseph disease: Altered motor axonal excitability properties and mexiletine treatment. Brain. 2003;126:965–73.
Ikeda H, Yamaguchi M, Sugai S, Aze Y, Narumiya S, Kakizuka A. Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo. Nat Genet. 1996;13:196–202.
Schmidt T, Lindenberg KS, Krebs A, Schöls L, Laccone F, Herms J, et al. Protein surveillance machinery in brains with spinocerebellar ataxia type 3: Redistribution and differential recruitment of 26S proteasome subunits and chaperones to neuronal intranuclear inclusions. Ann Neurol. 2002;51:302–10.
Cemal CK, Carroll CJ, Lawrence L, Lowrie MB, Ruddle P, Al Mahdawi S, et al. YAC transgenic mice carrying pathological alleles of the MJD1 locus exhibit a mild and slowly progressive cerebellar deficit. Hum Mol Genet. 2002;11:1075–94.
Goti D, Katzen SM, Mez J, Kurtis N, Kiluk J, Ben Haiem L, et al. A mutant ataxin-3 putative-cleavage fragment in brains of Machado-Joseph disease patients and transgenic mice is cytotoxic above a critical concentration. J Neurosci. 2004;24:10266–79.
Chai Y, Koppenhafer SL, Shoesmith SJ, Perez MK, Paulson HL. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro. Hum Mol Genet. 1999;8:673–82.
Schaffar G, Breuer P, Boteva R, Behrends C, Tzvetkov N, Strippel N, et al. Cellular toxicity of polyglutamine expansion proteins: Mechanism of transcription factor deactivation. Mol Cell. 2004;15:95–105.
Rüb U, de Vos RA, Brunt ER, Sebesteny T, Schöls L, Auburger G, et al. Spinocerebellar ataxia type 3 (SCA3): thalamic neurodegeneration occurs independently from thalamic ataxin-3 immunopositive neuronal intranuclear inclusions. Brain Pathol. 2006;16:218–27.
Rüb U, Brunt ER, Del Turco D, de Vos RA, Gierga K, Paulson H, et al. Guidelines for the pathoanatomical examination of the lower brain stem in ingestive and swallowing disorders and its application to a dysphagic spinocerebellar ataxia type 3 patient. Neuropathol Appl Neurobiol. 2003;29:1–13.
Iwabuchi K, Tsuchiya K, Uchihara T, Yagishita S. Autosomal dominant spinocerebellar degenerations. Clinical, pathological, and genetic correlations. Rev.Neurol (Paris). 1999;155:255–70.
Rüb U, Brunt ER, Petrasch-Parwez E, Schöls L, Theegarten D, Auburger G, et al. Degeneration of ingestion-related brainstem nuclei in spinocerebellar ataxia type 2, 3, 6 and 7. Neuropathol Appl Neurobiol. 2006;32:635–49.
Rüb U, Seidel K, Ozerden I, Gierga K, Brunt ER, Schöls L, et al. Consistent affection of the central somatosensory system in spinocerebellar ataxia type 2 and type 3 and its significance for clinical symptoms and rehabilitative therapy. Brain Res Rev. 2007;53:235–49.
Rüb U, Gierga K, Brunt ER, de Vos RA, Bauer M, Schöls L, et al. Spinocerebellar ataxias types 2 and 3: Degeneration of the pre-cerebellar nuclei isolates the three phylogenetically defined regions of the cerebellum. J Neural Transm. 2005;112:1523–45.
Rüb U, Brunt ER, de Vos RA, Del Turco D, Del Tredici K, Gierga K, et al. Degeneration of the central vestibular system in spinocerebellar ataxia type 3 (SCA3) patients and its possible clinical significance. Neuropathol Appl Neurobiol. 2004;30:402–14.
Rüb U, Del Turco D, Del Tredici K, de Vos RA, Brunt ER, Reifenberger G, et al. Thalamic involvement in a spinocerebellar ataxia type 2 (SCA2) and a spinocerebellar ataxia type 3 (SCA3) patient, and its clinical relevance. Brain. 2003;126:2257–72.
Rüb U, Brunt ER, Gierga K, Schultz C, Paulson H, de Vos RA, et al. The nucleus raphe interpositus in spinocerebellar ataxia type 3 (Machado-Joseph disease). J Chem Neuroanat. 2003;25:115–27.
Rüb U, Brunt ER, Gierga K, Seidel K, Schultz C, Schöls L, et al. Spinocerebellar ataxia type 7 (SCA7): First report of a systematic neuropathological study of the brain of a patient with a very short expanded CAG-repeat. Brain Pathol. 2005;15:287–95.
Gierga K, Bürk K, Bauer M, Orozco DG, Auburger G, Schultz C, et al. Involvement of the cranial nerves and their nuclei in spinocerebellar ataxia type 2 (SCA2). Acta Neuropathol. 2005;109:617–31.
Rüb U, Del Turco D, Burk K, Diaz GO, Auburger G, Mittelbronn M, et al. Extended pathoanatomical studies point to a consistent affection of the thalamus in spinocerebellar ataxia type 2. Neuropathol Appl Neurobiol. 2005;31:127–40.
Gilman S. The spinocerebellar ataxias. Clin Neuropharmacol. 2000;23:296–303.
Paulson HL, Perez MK, Trottier Y, Trojanowski JQ, Subramony SH, Das SS, et al. Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron. 1997;19:333–44.
Yamada M, Tan CF, Inenaga C, Tsuji S, Takahashi H. Sharing of polyglutamine localization by the neuronal nucleus and cytoplasm in CAG-repeat diseases. Neuropathol Appl Neurobiol. 2004;30:665–75.
Ichikawa Y, Goto J, Hattori M, Toyoda A, Ishii K, Jeong SY, et al. The genomic structure and expression of MJD, the Machado-Joseph disease gene. J Hum Genet. 2001;46:413–22.
Schmidt T, Landwehrmeyer GB, Schmitt I, Trottier Y, Auburger G, Laccone F, et al. An isoform of ataxin-3 accumulates in the nucleus of neuronal cells in affected brain regions of SCA3 patients. Brain Pathol. 1998;8:669–79.
Nishiyama K, Murayama S, Goto J, Watanabe M, Hashida H, Katayama S, et al. Regional and cellular expression of the Machado-Joseph disease gene in brains of normal and affected individuals. Ann Neurol. 1996;40:776–81.
Wang Q, Li L, Ye Y. Regulation of retrotranslocation by p97-associated deubiquitinating enzyme ataxin-3. J Cell Biol. 2006;174:963–71.
Hofmann K, Falquet L. A ubiquitin-interacting motif conserved in components of the proteasomal and lysosomal protein degradation systems. Trends Biochem Sci. 2001;26:347–50.
Burnett B, Li F, Pittman RN. The polyglutamine neurodegenerative protein ataxin-3 binds polyubiquitylated proteins and has ubiquitin protease activity. Hum Mol Genet. 2003;12:3195–205.
Chai Y, Berke SS, Cohen RE, Paulson HL. Poly-ubiquitin binding by the polyglutamine disease protein ataxin-3 links its normal function to protein surveillance pathways. J Biol Chem. 2004;279:3605–11.
Wang G, Sawai N, Kotliarova S, Kanazawa I, Nukina N. Ataxin-3, the MJD1 gene product, interacts with the two human homologs of yeast DNA repair protein RAD23, HHR23A and HHR23B. Hum Mol Genet. 2000;9:1795–803.
Doss-Pepe EW, Stenroos ES, Johnson WG, Madura K. Ataxin-3 interactions with rad23 and valosin-containing protein and its associations with ubiquitin chains and the proteasome are consistent with a role in ubiquitin-mediated proteolysis. Mol Cell Biol. 2003;23:6469–83.
Ryu KS, Lee KJ, Bae SH, Kim BK, Kim KA, Choi BS. Binding surface mapping of intra- and interdomain interactions among hHR23B, ubiquitin, and polyubiquitin binding site 2 of S5a. J Biol Chem. 2003;278:36621–7.
Hiyama H, Yokoi M, Masutani C, Sugasawa K, Maekawa T, Tanaka K, et al. Interaction of hHR23 with S5a. The ubiquitin-like domain of hHR23 mediates interaction with S5a subunit of 26 S proteasome. J Biol Chem. 1999;274:28019–25.
Boeddrich A, Gaumer S, Haacke A, Tzvetkov N, Albrecht M, Evert BO, et al. An arginine/lysine-rich motif is crucial for VCP/p97-mediated modulation of ataxin-3 fibrillogenesis. EMBO J. 2006;25:1547–58.
Hirabayashi M, Inoue K, Tanaka K, Nakadate K, Ohsawa Y, Kamei Y, et al. VCP/p97 in abnormal protein aggregates, cytoplasmic vacuoles, and cell death, phenotypes relevant to neurodegeneration. Cell Death Differ. 2001;8:977–84.
Higashiyama H, Hirose F, Yamaguchi M, Inoue YH, Fujikake N, Matsukage A, et al. Identification of ter94, Drosophila VCP, as a modulator of polyglutamine-induced neurodegeneration. Cell Death Differ. 2002;9:264–73.
Berke SJ, Chai Y, Marrs GL, Wen H, Paulson HL. Defining the role of ubiquitin-interacting motifs in the polyglutamine disease protein, ataxin-3. J Biol Chem. 2005;280:32026–34.
Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392:605–8.
Tsai YC, Fishman PS, Thakor NV, Oyler GA. Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function. J Biol Chem. 2003;278:22044–55.
Matsumoto M, Yada M, Hatakeyama S, Ishimoto H, Tanimura T, Tsuji S, et al. Molecular clearance of ataxin-3 is regulated by a mammalian E4. EMBO J. 2004;23:659–69.
Mao Y, Senic-Matuglia F, Di Fiore PP, Polo S, Hodsdon ME, De Camilli P. Deubiquitinating function of ataxin-3: insights from the solution structure of the Josephin domain. Proc Natl Acad Sci USA. 2005;102:12700–5.
Riley BE, Xu Y, Zoghbi HY, Orr HT. The effects of the polyglutamine repeat protein ataxin-1 on the UbL-UBA protein A1Up. J Biol Chem. 2004;279:42290–301.
Li F, Macfarlan T, Pittman RN, Chakravarti D. Ataxin-3 is a histone-binding protein with two independent transcriptional corepressor activities. J Biol Chem. 2002;277:45004–12.
Albrecht M, Hoffmann D, Evert BO, Schmitt I, Wüllner U, Lengauer T. Structural modeling of ataxin-3 reveals distant homology to adaptins. Proteins. 2003;50:355–70.
Masino L, Musi V, Menon RP, Fusi P, Kelly G, Frenkiel TA, et al. Domain architecture of the polyglutamine protein ataxin-3: A globular domain followed by a flexible tail. FEBS Lett. 2003;549:21–5.
Masino L, Kelly G, Leonard K, Trottier Y, Pastore A. Solution structure of polyglutamine tracts in GST-polyglutamine fusion proteins. FEBS Lett. 2002;513:267–72.
Altschuler EL, Hud NV, Mazrimas JA, Rupp B. Random coil conformation for extended polyglutamine stretches in aqueous soluble monomeric peptides. J Pept Res. 1997;50:73–5.
Chen S, Berthelier V, Yang W, Wetzel R. Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity. J Mol Biol. 2001;311:173–82.
Bevivino AE, Loll PJ. An expanded glutamine repeat destabilizes native ataxin-3 structure and mediates formation of parallel beta-fibrils. Proc Natl Acad Sci USA. 2001;98:11955–60.
Bennett MJ, Huey-Tubman KE, Herr AB, West AP, Jr., Ross SA, Bjorkman PJ. Inaugural Article: A linear lattice model for polyglutamine in CAG-expansion diseases. Proc Natl Acad Sci USA. 2002;99:11634–9.
Nicastro G, Menon RP, Masino L, Knowles PP, McDonald NQ, Pastore A. The solution structure of the Josephin domain of ataxin-3: structural determinants for molecular recognition. Proc Natl Acad Sci USA. 2005;102:10493–8.
Nicastro G, Habeck M, Masino L, Svergun DI, Pastore A. Structure validation of the Josephin domain of ataxin-3: Conclusive evidence for an open conformation. J Biomol NMR. 2006;36:267–77.
Scheel H, Tomiuk S, Hofmann K. Elucidation of ataxin-3 and ataxin-7 function by integrative bioinformatics. Hum Mol Genet. 2003;12:2845–52.
Holm L, Sander C. Protein structure comparison by alignment of distance matrices. J Mol Biol. 1993;233:123–38.
Hofmann B, Schomburg D, Hecht HJ. Crystal structure of a thiol proteinase from staphylococcus aureus V-8 in the E-64 inhibitor complex. Acta Cryst Sect. 1993;A49:102.
Zhu M, Shao F, Innes RW, Dixon JE, Xu Z. The crystal structure of Pseudomonas avirulence protein AvrPphB: A papain-like fold with a distinct substrate-binding site. Proc Natl Acad Sci USA. 2004;101:302–7.
Drenth J, Kalk KH, Swen HM. Binding of chloromethyl ketone substrate analogues to crystalline papain. Biochemistry. 1976;15:3731–8.
Johnston SC, Riddle SM, Cohen RE, Hill CP. Structural basis for the specificity of ubiquitin C-terminal hydrolases. EMBO J. 1999;18:3877–87.
Hu M, Li P, Li M, Li W, Yao T, Wu JW, et al. Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde. Cell. 2002;111:1041–54.
Wenig K, Chatwell L, Pawel-Rammingen U, Bjorck L, Huber R, Sondermann P. Structure of the streptococcal endopeptidase IdeS, a cysteine proteinase with strict specificity for IgG. Proc Natl Acad Sci USA. 2004;101:17371–6.
Fujiwara K, Tenno T, Sugasawa K, Jee JG, Ohki I, Kojima C, et al. Structure of the ubiquitin-interacting motif of S5a bound to the ubiquitin-like domain of HR23B. J Biol Chem. 2004;279:4760–7.
Perez MK, Paulson HL, Pendse SJ, Saionz SJ, Bonini NM, Pittman RN. Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation. J Cell Biol. 1998;143:1457–70.
Berke SJ, Schmied FA, Brunt ER, Ellerby LM, Paulson HL. Caspase-mediated proteolysis of the polyglutamine disease protein ataxin-3. J Neurochem. 2004;89:908–18.
Haacke A, Broadley SA, Boteva R, Tzvetkov N, Hartl FU, Breuer P. Proteolytic cleavage of polyglutamine-expanded ataxin-3 is critical for aggregation and sequestration of nonexpanded ataxin-3. Hum Mol Genet. 2006;15:555–68.
Warrick JM, Paulson HL, Gray-Board, Bui QT, Fischbeck KH, Pittman RN, et al. Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila. Cell. 1998;93:939–49.
Ghosh S, Feany MB. Comparison of pathways controlling toxicity in the eye and brain in drosophila models of human neurodegenerative diseases. Hum Mol Genet. 2004;13:2011–8.
Warrick JM, Chan HY, Gray-Board , Chai Y, Paulson HL, Bonini NM. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat Genet. 1999;23:425–8.
Kazemi-Esfarjani P, Benzer S. Suppression of polyglutamine toxicity by a Drosophila homolog of myeloid leukemia factor 1. Hum Mol Genet. 2002;11:2657–72.
Warrick JM, Morabito LM, Bilen J, Gordesky-Gold B, Faust LZ, Paulson HL, et al. Ataxin-3 suppresses polyglutamine neurodegeneration in Drosophila by a ubiquitinassociated mechanism. Mol Cell. 2005;18:37–48.
Chai Y, Koppenhafer SL, Bonini NM, Paulson HL. Analysis of the role of heat shock protein (Hsp) molecular chaperones in polyglutamine disease. J Neurosci. 1999;19:10338–47.
Kretzschmar D, Tschape J, Bettencourt DC, Asan E, Poeck B, Strauss R, et al. Glial and neuronal expression of polyglutamine proteins induce behavioral changes and aggregate formation in Drosophila. Glia. 2005;49:59–72.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Riess, O., Rüb, U., Pastore, A. et al. SCA3: Neurological features, pathogenesis and animal models. Cerebellum 7, 125–137 (2008). https://doi.org/10.1007/s12311-008-0013-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12311-008-0013-4